JPWO2022198001A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022198001A5 JPWO2022198001A5 JP2023557284A JP2023557284A JPWO2022198001A5 JP WO2022198001 A5 JPWO2022198001 A5 JP WO2022198001A5 JP 2023557284 A JP2023557284 A JP 2023557284A JP 2023557284 A JP2023557284 A JP 2023557284A JP WO2022198001 A5 JPWO2022198001 A5 JP WO2022198001A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- treatment
- cancer
- refractory
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162691P | 2021-03-18 | 2021-03-18 | |
| US63/162,691 | 2021-03-18 | ||
| PCT/US2022/020878 WO2022198001A1 (en) | 2021-03-18 | 2022-03-18 | Use of sephb4-hsa fusion protein as a first-line therapy in cancer treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024511995A JP2024511995A (ja) | 2024-03-18 |
| JPWO2022198001A5 true JPWO2022198001A5 (https=) | 2025-06-23 |
| JP2024511995A5 JP2024511995A5 (https=) | 2025-06-23 |
Family
ID=83320877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557284A Pending JP2024511995A (ja) | 2021-03-18 | 2022-03-18 | がん治療における第一選択療法としてのｓＥｐｈＢ４－ＨＳＡ融合タンパク質の使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240156908A1 (https=) |
| EP (1) | EP4308149A4 (https=) |
| JP (1) | JP2024511995A (https=) |
| KR (1) | KR20230173108A (https=) |
| CN (1) | CN117120074A (https=) |
| AU (1) | AU2022239581A1 (https=) |
| CA (1) | CA3211742A1 (https=) |
| WO (1) | WO2022198001A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274305B1 (en) * | 1996-12-19 | 2001-08-14 | Tufts University | Inhibiting proliferation of cancer cells |
| EP3368551B1 (en) * | 2015-10-27 | 2023-07-12 | The University Of Queensland | A modified epha4 polypeptide |
| CA3139416A1 (en) * | 2019-02-13 | 2020-08-20 | Vasgene Therapeutics Inc | Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer |
| WO2020190977A1 (en) * | 2019-03-17 | 2020-09-24 | Vasgene Therapeutics Inc | Treatment of cancers using sephb4-hsa fusion proteins |
-
2022
- 2022-03-18 CA CA3211742A patent/CA3211742A1/en active Pending
- 2022-03-18 EP EP22772256.8A patent/EP4308149A4/en active Pending
- 2022-03-18 US US18/282,538 patent/US20240156908A1/en active Pending
- 2022-03-18 KR KR1020237035777A patent/KR20230173108A/ko active Pending
- 2022-03-18 AU AU2022239581A patent/AU2022239581A1/en active Pending
- 2022-03-18 JP JP2023557284A patent/JP2024511995A/ja active Pending
- 2022-03-18 CN CN202280022432.5A patent/CN117120074A/zh active Pending
- 2022-03-18 WO PCT/US2022/020878 patent/WO2022198001A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Toripalimab: the first domestic anti-tumor PD-1 antibody in China | |
| Caponigro et al. | Treatment approaches to nasopharyngeal carcinoma: a review | |
| Zaidi et al. | Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-cell mediated anti-tumor immunity in an esophageal adenocarcinoma model | |
| JP2017537090A5 (https=) | ||
| JP2020514290A5 (https=) | ||
| JP2020508317A5 (https=) | ||
| KR20220162844A (ko) | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 | |
| TW202330589A (zh) | 治療 | |
| Caponigro et al. | Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors | |
| JP2008508858A (ja) | マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害 | |
| CN113087797B (zh) | 抗犬pd-1抗体及其应用 | |
| van der Wilk et al. | The optimal neoadjuvant treatment of locally advanced esophageal cancer | |
| JP2020512978A5 (https=) | ||
| CN113677707A (zh) | 用于在治疗癌症中增强效力的il-4/il-13途径抑制剂 | |
| Gampenrieder et al. | Treatment landscape for patients with HER2-positive metastatic breast cancer: a review on emerging treatment options | |
| JP2003511019A (ja) | Ｉｌ１３変異体 | |
| Ning et al. | Recent progress in antibody-based therapeutics for triple-negative breast cancer | |
| Qureshi et al. | Immunotherapy approaches beyond PD-1 inhibition: the future of cellular therapy for head and neck squamous cell carcinoma | |
| JP2020537690A (ja) | プレクチン１結合抗体およびその使用 | |
| TW202328212A (zh) | Ｍａｇｅ—ａ４陽性癌症之治療 | |
| TWI899236B (zh) | 通過投予pd-1抑制劑治療子宮頸癌的方法 | |
| JPWO2022198001A5 (https=) | ||
| Clark et al. | Recent progress in systemic treatment for lung cancer | |
| JPWO2020190977A5 (https=) | ||
| Gerber et al. | Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC |